We previously developed a monoclonal antibody (mAb) that targets the membrane form of claudin-1 (CLDN1) and showed that it could inhibit the growth of colon cancer cells expressing CLDN1, suggesting that CLDN1 targeting could be of clinical benefit for a subset of CRC patients [19]. This evidence concerns the gene CLDN1 and malignant colon neoplasm.